Targeted Therapy Towards Cancer-A Perspective.
Radionuclide antibody conjugates (RACs) and antibody-drug conjugates (ADCs) can function as biotherapeutic missiles in order to target cancer cells and destroy them. The advent of new technology platforms consisting of imaging modalities, drug design and radiochemistry will facilitate the personalised approach for cancer patient treatment programmes. The utilisation of radionuclides and cytotoxic drugs conjugated to biovectors can deliver a cytotoxic drug payload with the ability to emit alpha and/or beta particles in the vicinity of the tumour by binding onto the cancer cells surface antigens initiating cell death. This perspective aims to provide an insight into targeted therapies in the treatment of various cancerous disease states including breast cancer, prostate bone metastases, lymphoma and leukaemia.
Department of Biocatalysis and Isotope Chemistry, Almac, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, United Kingdom.
Sean L
SL
Kitson
Nuclear Medicine Unit, Department of Clinical and Experimental Internistic, Italy.
Vincenzo
V
Cuccurullo
Nuclear Medicine Department, S. Andrea Hospital, La Spezia, Italy.
Andrea
A
Ciarmiello
Nuclear Medicine Unit, Department of Clinical and Experimental Internistic, Italy.
Luigi
L
Mansi
D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013329:Structure-Activity Relationship
D000903:Antibiotics, Antineoplastic
Radiometal; antibody-drug conjugates (ADCs); biovectors; cancer; radionuclide antibody conjugates; targeted alpha therapy